A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT02804763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
Study identification
- NCT ID
- NCT02804763
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2016 (Actual)
- Primary completion
- May 31, 2018 (Actual)
- Completion
- Nov 19, 2018 (Actual)
- Last update posted
- Jun 30, 2021
2016 – 2018
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sl0023 312 | Birmingham | Alabama | 35294 | — |
| Sl0023 307 | El Cajon | California | 92020 | — |
| Sl0023 309 | El Cajon | California | 92020 | — |
| Sl0023 323 | Huntington Beach | California | 92646 | — |
| Sl0023 311 | Los Angeles | California | 90048 | — |
| Sl0023 314 | Thousand Oaks | California | 91360 | — |
| Sl0023 302 | Upland | California | 91786 | — |
| Sl0023 326 | New Haven | Connecticut | 06520 | — |
| Sl0023 304 | Clearwater | Florida | 33765 | — |
| Sl0023 322 | DeBary | Florida | 32713 | — |
| Sl0023 321 | Miami | Florida | 33136 | — |
| Sl0023 301 | Miami Lakes | Florida | 33014 | — |
| Sl0023 319 | Palm Harbor | Florida | 34684 | — |
| Sl0023 310 | Tampa | Florida | 33603 | — |
| Sl0023 324 | Atlanta | Georgia | 30303 | — |
| Sl0023 327 | Stockbridge | Georgia | 30281 | — |
| Sl0023 320 | Idaho Falls | Idaho | 83404 | — |
| Sl0023 306 | Albuquerque | New Mexico | 87104 | — |
| Sl0023 313 | Lake Success | New York | 11042 | — |
| Sl0023 305 | Oklahoma City | Oklahoma | 73101 | — |
| Sl0023 315 | Jackson | Tennessee | 38305 | — |
| Sl0023 308 | Memphis | Tennessee | 38119 | — |
| Sl0023 317 | Amarillo | Texas | 79124 | — |
| Sl0023 303 | Houston | Texas | 77034 | — |
| Sl0023 328 | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02804763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02804763 live on ClinicalTrials.gov.